⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9636001 | 0.85 | — | — | |
| SCHEMBL2107266 | 0.78 | — | — | |
| SCHEMBL10378067 | 0.77 | — | — | |
| SCHEMBL4349098 | 0.77 | — | — | |
| SCHEMBL18857997 | 0.77 | — | — | |
| SCHEMBL11608061 | 0.76 | — | — | |
| SCHEMBL1701326 | 0.75 | HPGD (0.46) | — | |
| SCHEMBL21172135 | 0.75 | LMNA (0.38) | — | |
| Dimethylamine SCHEMBL28005508 | 0.74 | HPGD (0.39) | — | |
| SCHEMBL7317695 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027919-A1 | Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase | AMICUS THERAPEUTICS INC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9402837-B2 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | AMICUS THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9119845-B2 | Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase | Amicus Therapeautics, Inc. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150025109-A1 | Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase | AMICUS THERAPEUTICS INC (US) | 2015-01-22 | — | — | US | disclosed |